Cash Flow from Investing Activities: The total change in cash resulting from a company's investments.
Innate Pharma SA (IPHYF) had Cash Flow from Investing Activities of $8.25M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
| Balance Sheet Financials | |
$52.85M |
|
-- |
|
$13.18M |
|
$70.96M |
|
$41.47M |
|
-- |
|
$54.05M |
|
$95.52M |
|
$-24.55M |
|
$-24.56M |
|
$-24.56M |
|
-- |
|
| Cash Flow Statement Financials | |
$-59.69M |
|
|
Cash Flow from Investing Activities |
$8.25M |
$6.87M |
|
$75.12M |
|
$31.78M |
|
$-43.34M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|